Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation
- Hamid, A.R.
- Verhaegh, G.W.C.T.
- Smit, F.P.
- RIjt-van de Westerlo, C.
- Armandari, I.
- Brandt, A.
- Sweep, C.G.J.
- Sedelaar, J.P.M.
- Schalken, J.A.
DOIAbstract
Item does not contain fulltextPURPOSE: Dihydrotestosterone is the main active androgen in the prostate and it has a role in prostate cancer progression. After androgen deprivation therapy androgen receptor signaling is still active in tumor cells. Persistent intratumor steroidogenesis and androgen receptor changes are responsible for this continued activity, which influences the efficacy of prostate cancer treatment. We hypothesized that combining a 5alpha-reductase inhibitor and an antiandrogen would block intratumor androgen synthesis and androgen receptor protein activity. Thus, it would act synergistically to reduce tumor cell proliferation. MATERIALS AND METHODS: The expression level of 5alpha-reductase and androgen receptor in endocri...
Add to ORKG